We evaluated the expression of BCL2 in bone marrow CD34+ cells from a cohort of MDS and chronic myelomonocytic leukemia patients with and without ASXL1 mutations [7]. This evidence concerns the gene BCL2 and chronic myelomonocytic leukemia.